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Prevention of Atrial Fibrillation
Recurrence With Corticosteroids
After Radiofrequency Catheter Ablation
A Randomized Controlled Trial
Takashi Koyama, MD, Hiroshi Tada, MD, Yukio Sekiguchi, MD, Takanori Arimoto, MD,
Hiro Yamasaki, MD, Kenji Kuroki, MD, Takeshi Machino, MD, Kazuko Tajiri, MD,
Xu Dong Zhu, MD, Miyako Kanemoto-Igarashi, MD, Aiko Sugiyasu, MD, Keisuke Kuga, MD,
Yoshio Nakata, PHD, Kazutaka Aonuma, MD
Tsukuba, Japan
Objectives We sought to clarify the efficacy of corticosteroid therapy for preventing atrial fibrillation (AF) recurrence after
pulmonary vein isolation (PVI).
Background The inflammatory process may cause acute AF recurrence after PVI. However, no studies have examined the
relationship between corticosteroid administration and AF recurrence after PVI.
Methods A total of 125 patients with paroxysmal AF were randomized to receive either corticosteroids (corticosteroid
group) or a placebo (placebo group). In the corticosteroid group, intravenous hydrocortisone (2 mg/kg) was given
the day of the procedure, and oral prednisolone (0.5 mg/kg/day) was administered for 3 days after the PVI. The
body temperature and high-sensitivity C-reactive protein level were measured before and on each of the first
3 days after ablation.
Results The prevalence of immediate AF recurrence (3 days after the PVI) was significantly lower in the corticosteroid
group (7%) than in the placebo group (31%). The maximum body temperature and C-reactive protein during the
initial 3 days after ablation and the increase in the body temperature and C-reactive protein level from baseline
were significantly lower in the corticosteroid group than in the placebo group. Corticosteroid treatment did not
decrease AF recurrences between 4 and 30 days after ablation. The AF-free rate at 14 months post-ablation was
greater in the corticosteroid group (85%) than in the placebo group (71%, p  0.032 by the log-rank test).
Conclusions Transient use of small amounts of corticosteroids shortly after AF ablation may be effective and safe for prevent-
ing not only immediate AF recurrences but also AF recurrences during the mid-term follow-up period after PVI.
(J Am Coll Cardiol 2010;56:1463–72) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.04.057e
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rulmonary vein isolation (PVI) is becoming an effective
herapeutic option for drug-refractory, paroxysmal atrial
brillation (AF). However, the rate of AF recurrence after
uccessful PVI remains relatively high (1), and recurrences
ommonly occur within the first several weeks after the PVI
2–4). There is much evidence of a mechanistic link
etween inflammatory processes and the development of
F (5,6). Electrical PVI by radiofrequency energy causes
rom the Cardiovascular Division, Institute of Clinical Medicine, Graduate School of
omprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan. The
uthors have reported that they have no relationships to disclose.c
Manuscript received October 20, 2009; revised manuscript received March 10,
010, accepted April 13, 2010.xtensive myocardial damage, which may result in a sys-
emic and local inflammatory response (7,8). Recent studies
ave found that inflammatory responses appeared shortly
fter PVI (7,8) and that those responses were closely
ssociated with AF recurring within the initial 3 days after
See page 1473
he procedure (7). Several studies have reported that corti-
osteroids reduce AF after cardiac surgery by preventing
nflammatory reactions (9). Therefore, we hypothesized that
orticosteroid therapy might negate AF recurrences imme-
iately after PVI by preventing post-ablation inflammatory
esponses. This study was designed and undertaken to
larify this point.
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Patients. Between April 2007
and March 2008, 130 consecu-
tive patients with drug-refractory
AF were enrolled in this study
(Table 1). All patients were
newly enrolled in this study, and
none had a history of ablation.
All patients had symptomatic,
paroxysmal AF, which was de-
fined as AF episodes that spon-
taneously terminate and last for
30 s and 7 days during treat-
ment with antiarrhythmic drugs
(AADs) (7). All AADs were dis-
ontinued 5 half-lives before the ablation procedure with
he exception of amiodarone, which was discontinued at
east 6 weeks before and the other drugs were administered
ntil the end of the study period. The study was approved by
Baseline Patient Characteristics and Results ofTable 1 Baseline Patient Characteristics an
All Patients
(n  125)
Age, yrs 60.7 9.6
Male sex 100 (80.0)
Duration of AF, yrs 7.3 5.7
Underlying heart disease
Hypertension 65 (52.0)
Coronary artery disease 10 (8.0)
Valvular heart disease 15 (12.0)
No structural heart disease 100 (80.0)
Antiarrhythmic drugs
Class I 103 (82.4)
Class Ia 23 (18.4)
Class Ib 13 (10.4)
Class Ic 80 (64.0)
Class III 56 (44.8)
Class IV 18 (14.4)
Medication
ACEIs or ARBs 62 (49.6)
Beta-blockers 56 (44.8)
Statins 43 (34.4)
Echocardiographic parameters
LA diameter, mm 38.3 7.4
LV end-diastolic dimension, mm 48.3 4.9
LV ejection fraction, % 64.4 8.8
Results of catheter ablation
Total duration of procedure, min 205.1 34.3
Total fluoroscopy time, min 81.4 24.4
Duration of RF energy, min 48.1 17.6
Total RF energy delivered (103 J) 68.1 32.9
Additional ablation procedures
LA roof line 10 (8)
SVC isolation 7 (5.6)
Values are reported as mean  SD or n (%).
Abbreviations
and Acronyms
AAD  antiarrhythmic drug
AF  atrial fibrillation
APC  atrial premature
contraction
BT  body temperature
CI  confidence interval
CRP  C-reactive protein
OR  odds ratio
PV  pulmonary vein
PVI  pulmonary vein
isolationACEI angiotensin-converting enzyme inhibitor; AF atrial fibrillation; ARB
RF  radiofrequency; SVC  superior vena cava.n institutional review committee, and all patients gave their
ritten informed consent before participation.
tudy protocol. This study was designed as a prospective,
andomized, double-blind study. All patients were random-
zed for treatment with corticosteroids (corticosteroid
roup) or a placebo (placebo group) on the first day of their
ospitalization and were observed prospectively after a
ingle PVI procedure (Fig. 1).
In the corticosteroid group, 1 mg per 1 ml hydrocortisone
odium succinate (Solu-Cortef, Pfizer Manufacturing,
uurs, Belgium) in a 0.9% sodium chloride solution was
dministered intravenously (2-mg/kg dose) immediately
fter the procedure. Oral prednisolone (Takeda Pharmaceu-
ical Co., Tokyo, Japan) was also administered (0.5 mg/kg/
ay) for 3 days after the PVI. A placebo solution (0.9%
odium chloride, 1 ml/kg) and oral drug (lactose) were
dministered in a manner similar to that in the placebo
roup patients.
Within each group, the patients were divided into 3
ubgroups according to the results of the AF recurrence
eter Ablationsults of Catheter Ablation
Placebo
(n  65)
Corticosteroid
(n  60) p Value
61.5 10.3 59.8 8.7 0.33
52 (80.0) 48 (80.0) 1.00
5.8 4.6 8.8 6.4 0.01
29 (44.6) 36 (55.4) 0.87
6 (9.2) 4 (6.7) 0.60
9 (13.8) 6 (10.0) 0.51
50 (76.9) 50 (83.3) 0.37
51 (78.5) 52 (86.7) 0.59
11 (16.9) 12 (20.0) 0.66
6 (9.2) 7 (11.7) 0.66
39 (60.0) 41 (68.3) 0.21
33 (50.8) 23 (38.3) 0.31
6 (9.2) 12 (20.0) 0.08
29 (44.6) 33 (55.0) 0.93
24 (36.9) 32 (53.3) 0.19
24 (36.9) 19 (31.7) 0.54
38.9 7.7 37.6 7.1 0.34
48.3 4.5 48.4 5.3 0.95
62.8 9.8 66.1 7.3 0.31
209.1 32.6 200.8 35.6 0.27
82.6 24.3 81.4 22.3 0.42
48.2 19.3 47.9 15.8 0.94
64.4 32.9 72.1 32.8 0.23
4 (6.1) 6 (10) 0.43
3 (4.6) 4 (6.6) 0.62Cathd Re angiotensin receptor blocker; LA left atrial; LV left ventricular;
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October 26, 2010:1463–72 Corticosteroids Suppress AF After Ablationuring the initial 1 month after ablation (7): immediate AF
ecurrence group, early AF recurrence group, and non-AF
ecurrence group. Immediate and early AF recurrences were
efined as AF episodes that occurred within 3 days and
etween 4 and 30 days after the PVI, respectively. Non-AF
ecurrence was defined as no AF after the PVI.
The primary end point of the study was the proportion of
atients free of recurrent AF, and the secondary end point
as recurrent AF and any serious complications caused by
atheter ablation or treatment with corticosteroid.
atheter ablation. Extensive PVI was performed using the
ouble Lasso technique (7) without a 3-dimensional map-
ing system. A 7-F deflectable catheter with an 8-mm distal
lectrode (Ablaze, Japan Lifeline Co., Tokyo, Japan) was
sed for ablation in the temperature control mode at a target
emperature of 52°C and maximum power output of 30 to
5 W. Two fluoroscopic angles were used for confirming
he catheter position. The end point of the PVI was the
reation of a bidirectional conduction block from the atrium
o the PVs and vice versa (7). After the PVI, if AF was
ustained or induced with coronary sinus burst pacing at a
ycle length down to 180 ms during the administration of
ntravenous isoproterenol (1.0 to 3.0 g/min) and lasted
ore than 3 min (7,10), additional ablation, consisting of
inear ablation of the left atrial roof and/or superior vena
ava isolation, was performed. If the AF did not terminate or
as inducible after these procedures, sinus rhythmwas restored
y transthoracic cardioversion (10). A cavotricuspid isthmus
lock line was created in all patients with confirmation of
65
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(31%)
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(18%)
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(29%)
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(71
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Figure 1 Flow Diagram and Results of the Present Study
AF  atrial fibrillation; PV  pulmonary vein.idirectional block. tollow-up. Patients remained hospitalized under continu-
us rhythm monitoring (CNS-970, Nihon Kohden, Tokyo,
apan) for at least 1 week after the procedure and were
ollowed for 14 months after the PVI procedure. After
ischarge, all patients underwent follow-up at 2 weeks
ost-procedure and then every month thereafter. At each
ospital visit, the patients underwent 12-lead electrocardiog-
aphy and intensive questioning regarding any arrhythmia-
elated symptoms. Holter monitoring for 24 h was performed
t 2 weeks and 1, 3, 6, and 14 months after the PVI. Portable
lectrocardiographic monitoring (HCG-901, OMRON,
yoto, Japan) was also performed for 3 min twice daily
morning and night for a total 6 min/day) on 3 consecutive
ays at 2 weeks and 1, 3, 6, and 14 months after the PVI.
welve-lead electrocardiography, 24-h Holter electrocardiog-
aphy, and portable electrocardiographic monitoring were also
sed any time that the patients reported palpitations. If the
lectrocardiogram showed any AF episodes during follow-up,
atients received a diagnosis of clinical recurrence of AF,
rrespective of the presence of symptoms (7). Patients with AF
ecurrence were treated temporarily with Class I, II, III, and/or
V AADs, and the AADs were discontinued if stable sinus
hythm could be maintained. Discontinuation of the AADs
as then attempted in those patients in whom the recurrent
F disappeared after temporary treatment; if sinus rhythm
ould be maintained, the drugs were stopped permanently.
epeat ablation was not performed in any of the patients
uring the study period.
ther definitions and data analysis. The patients’ body
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Corticosteroids Suppress AF After Ablation October 26, 2010:1463–72blation and every 6 h during the first 3 consecutive days
fter the PVI; the highest BT and maximum difference in
he BT (BT), defined as the difference between the
ighest BT during the first 3 days post-procedure and the
T measured before the ablation, were obtained. The BT
as measured by an electrical axillary thermometer (C202,
ERUMO, Tokyo, Japan) placed in the axilla of the arm
ot receiving a fluid infusion. After the patient rested in bed
or 20 min, the patient’s axilla was wiped free of sweat,
nd the BT was measured 3 times and averaged. The highly
ensitive C-reactive protein (CRP) level was also measured
efore and for 3 consecutive days after the PVI procedure;
he maximum CRP level and rise in the CRP (CRP),
efined as the difference between the maximum CRP and
RP before the ablation, were obtained (7). During the first
days after ablation, all patients were examined for the
resence of frequent atrial premature contractions (APCs),
efined as 10 APCs within 1 min, and nonsustained AF
asting for 30 s (7).
The recurrence of AF within the first month only was
onsidered transient (3,11). This first 1-month period was
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Figure 2 Differences in Clinical Parameters Between the Place
During the Initial 3 Days After a Pulmonary Vein Isola
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bottom). (B) Maximum level of C-reactive protein (CRP) (top) and the difference b
as the distribution (left) and mean  SD (right) for each group. (C) Prevalence of
(AF) (bottom).pplied as a blanking period and was used to classify the
atients into the 3 AF recurrence subgroups and to account
or the fact that AF recurrences early after the PVI may be
ransient and may not necessarily imply a failed ablation.
nly the prevalence of AF recurrences during the period
rom 31 days to 14 months after the ablation was examined.
tatistical analysis. From the results of a single procedure
utcome of PVI for paroxysmal AF (12,13) and a relative
ecrease in AF occurrences after cardiac surgery (9), we
ssumed that sinus rhythm would be present at 14 months
fter ablation in 80% of patients who received corticosteroid
herapy after the ablation and in 50% of patients who did
ot. We estimated that a minimum of 52 patients were
equired in each group to give the study a statistical power
f 90% with a 2-tailed alpha value of 0.05. Continuous
ariables are expressed as the mean  SD. A Student t test
r analysis of variance with a Tukey analysis was used to
nalyze the differences between groups, as appropriate. For
on-normally distributed data, a Kruskal-Wallis test was
sed when comparing more than 3 groups, and the Mann-
hitney U test was used when comparing 2 groups.
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October 26, 2010:1463–72 Corticosteroids Suppress AF After Ablationategorical variables were compared by a chi-square anal-
sis and Yates correction, if necessary. A univariate and
ultivariate logistic regression analysis was used to identify
redictors of immediate and early AF recurrences. A Cox
egression analysis was also used to identify predictors of AF
ecurrences during the 14-month follow-up period. All
arameters with a significance 0.10 in the univariate
nalysis were entered into the multivariate model. A
eceiver-operator characteristic curve analysis was used to
etermine the ability of the BT or CRP level to predict AF
ecurrences. The time to AF recurrences was estimated by
he Kaplan-Meier method, with comparisons made using
he log-rank test. A p value 0.05 was considered
ignificant.
esults
tudy design and participants. In the corticosteroid
roup, 5 patients were excluded from this study: 3 refused to
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n the placebo group were excluded from this study. As a
esult, 125 patients were enrolled and randomized under
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roup (n  65) (Fig. 1).
aseline characteristics and acute results of catheter
blation. Although the duration of an AF history was
onger in the corticosteroid group than placebo group (p 
.01), no significant differences were found in terms of the
ther variables between the 2 groups (Table 1). Extensive
VI and cavotricuspid isthmus ablation were successfully
erformed in all patients, and bidirectional conduction block
as created at all 4 PVs and the cavo-tricuspid isthmus.
inear ablation of the left atrial roof and/or superior vena
ava isolation were performed in 10 patients with sustained
F (n  3) or induced AF lasting more than 3 min (n  7)
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Corticosteroids Suppress AF After Ablation October 26, 2010:1463–72Table 1). A mitral isthmus line was not created in any of
he patients. Catheter ablation parameters and prevalence of
dditional ablation were comparable between the 2 groups
Table 1).
F recurrence during the initial 1-month follow-up
eriod after ablation. During the initial 1 month after
blation, AF recurrences were observed less frequently in
he corticosteroid group (16 patients, 27%) than in the
lacebo group (32 patients, 49%; p  0.01) (Fig. 1). A
ubgroup analysis of the patients in the 2 groups showed the
revalence of early AF recurrences in the corticosteroid
roup (20%) was comparable to that (18%) in the placebo
roup (p  0.9). However, the prevalence of immediate AF
ecurrences in the corticosteroid group (7%) was less than
hat in the placebo group (31%; p  0.001) (Fig. 1).
nflammatory responses, pericarditis, and atrial arrhythmias
uring the initial 3 days after ablation. During the initial
days after the PVI, the highest BT (p  0.005) and BT
p  0.001) were both lower in the corticosteroid group
Fig. 2A). The maximum CRP and CRP in the cortico-
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atient reported slight chest pain transiently with deep
reaths, but no pericardial effusion or electrocardiographic
hanges suggestive of pericarditis were found. The preva-
ence of frequent APCs and nonsustained AF did not differ
etween the 2 groups (Fig. 2C).
ubgroup analysis of inflammatory responses. In the
lacebo group, both the highest BT andBT during the initial
days after the PVI were greater in the immediate AF
ecurrence group than the other 2 subgroups (both p 0.001)
Fig. 3A); however, in the corticosteroid group, these variables
ere comparable among the 3 subgroups (Fig. 3B). In the
lacebo group, both the maximum CRP and CRP in the
mmediate AF recurrence group were the highest among the 3
ubgroups (maximum CRP; p  0.001, CRP; p  0.001)
Fig. 4A). However, in the corticosteroid group, there was no
ignificant difference in these variables among the 3 subgroups
Fig. 4B). The leukocyte count was comparable among the 3
ubgroups of both groups (data not shown).
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October 26, 2010:1463–72 Corticosteroids Suppress AF After AblationIn the placebo and corticosteroid groups, frequent APCs
nd nonsustained AF were observed more often in the early
F recurrence group than in the immediate AF recurrence
nd no AF recurrence groups, and the differences among the
subgroups were statistically significant in both groups
Figs. 5A and 5B). No significant differences were found for
hese variables among the subgroups of the placebo and
orticosteroid groups.
ost-ablation course and resolution of AF recurrences.
uring the ablation procedure and 14-month follow-up, no
ajor complications occurred in any patients. Groin hem-
rrhages occurred in 2 patients but resolved with manual
nd bandage compression.
In the placebo group, recurrent AF attacks disappeared in
4 (70%) of 20 patients with immediate AF recurrences and
n 4 (33%) of 12 with early AF recurrences between 31 days
nd 14 months after the PVI (Fig. 1). However, in the
orticosteroid group, recurrent AF attacks disappeared in all
(100%) patients with immediate AF recurrences and in 6
0
25
50
75
100
N
on
-S
us
ta
in
ed
 A
F 
(%
)
0
25
50
75
100
A
P
C
s 
(%
)
A Placebo
3/20
7/12
2/33
8/12
4/20
2/33
B
p < 0.001p <0.05
p <0.05
p < 0.001p <0.05
p =0.53
Immediate
recurrence
Early
recurrence
No
recurrence
Immediate
recurrence
Early
recurrence
No
recurrence
Figure 5 Relationship Between the AF Recurrence Patterns an
(A) Placebo group. (B) Corticosteroid group. Abbreviations as in Figure 2.50%) of 12 with early AF recurrences during that period.
hus, the prevalence of no AF recurrences without any
ntiarrhythmic drugs at 14 months post-ablation was
reater in the corticosteroid group (85%) than in the placebo
roup (71%; p  0.05) (Fig. 1). No sustained atrial
achycardia was observed in any patients in either group
uring this period.
The prevalence of an AF-free rate at 14 months post-
blation in the subgroup analysis of the patients with
mmediate AF recurrences was higher in the corticosteroid
roup than in the placebo group (4 of 4 [100%] vs. 14 of 20
70%]; p  0.05) (Fig. 1). However, it was comparable in
he patients with early AF recurrences (corticosteroid group,
of 12 [50%] vs. placebo group, 14 of 20 [33%], p  0.43)
Fig. 1).
A Kaplan-Meier survival analysis showed that the AF-
ree rate without any antiarrhythmic drugs at 14 months
ost-ablation was greater in the corticosteroid group than in
he placebo group (p  0.032 by the log-rank test) (Fig. 6).
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Corticosteroids Suppress AF After Ablation October 26, 2010:1463–72redictors of AF recurrence after ablation. A logistic
egression analysis revealed that the BT (odds ratio [OR]:
2.33; 95% confidence interval [CI]: 7.076 to 147.7;
 0.001) and CRP (OR: 1.739; 95% CI: 1.007 to
.005; p  0.047) were associated with immediate AF
ecurrences (Table 2). APCs (OR: 15.96; 95% CI: 4.000
o 63.66; p  0.001), and nonsustained AF during the
nitial 3 days after ablation (OR: 20.57; 95% CI: 5.184 to
1.62; p  0.001) were associated with early AF recur-
ences (Table 3).
In the Cox regression analysis including the highest BT,
aximum CRP, frequent APCs, nonsustained AF, and
orticosteroid treatment, APCs (hazard ratio: 3.560; 95%
I: 1.809 to 7.007; p  0.001), and nonsustained AF
hazard ratio: 3.526, 95% CI: 1.856 to 6.697; p  0.001)
ere associated with AF recurrences during the follow-up
eriod (Table 4). Corticosteroid treatment decreased AF
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Figure 6 Kaplan-Meier Curve of the Freedom From AF
Kaplan-Meier plot of the effect of the corticosteroid treatment on the
incidence of recurrent atrial fibrillation (AF) after pulmonary vein isolation.
nivariate and Multivariate Analyses ofmmediate AF Recurrences fter Catheter AblationTable 2 Univariat and Multivariat Analyses ofImmediate AF Recurrences After Catheter Ablation
p Value Odds Ratio
95% Confidence
Interval
Univariate analysis
Frequent APCs 0.132 0.372 0.103–1.347
Nonsustained AF 0.894 0.922 0.281–3.026
Highest body temperature, °C 0.001 48.66 11.28–209.8
Body temperature, °C 0.001 34.81 9.086–133.3
Highest CRP, mg/dl 0.001 3.100 1.734–5.542
CRP, mg/dl 0.001 3.201 1.781–5.753
Corticosteroid treatment 0.002 0.161 0.051–0.504
Multivariate analysis
Highest body temperature, °C 0.001 32.33 7.076–147.7
Highest CRP, mg/dl 0.047 1.739 1.007–3.005
Corticosteroid treatment 0.310 0.466 0.107–2.031F  atrial fibrillation; APC  atrial premature contraction; CRP  C-reactive protein. Aecurrences during the follow-up period (hazard ratio:
.458; 95% CI: 0.226 to 0.929; p  0.031). By a receiver-
perator characteristic analysis, a post-CRP level of 1.21
g/dl was the threshold value for AF recurrences with
1.7% sensitivity and 97.2% specificity (area under the
urve: 0.871, p  0.001) and a BT of 37.6°C with 79.2%
ensitivity and 95.0% specificity could distinguish patients
ith AF recurrences (area under the curve: 0.905, p  0.001).
iscussion
ajor findings. The present study showed the following:
) acute inflammatory responses occurring during the initial
days after PVI were greater in patients with immediate
F recurrences than in those with early AF recurrences;
) corticosteroid treatment inhibited inflammatory re-
ponses and decreased immediate AF recurrences; 3) corti-
osteroid treatment was associated with fewer AF recur-
ences at 1 month after PVI and during the 14 months after
he initial 1-month follow-up; and 4) corticosteroid treat-
ent did not reduce early AF recurrences or affect the
F-free rate at 14 months in patients with early AF
ecurrences or no AF recurrences within 1 month after PVI.
nflammation and AF recurrences after ablation. The
RP levels were more than 2-fold higher in patients with
F than in control patients, and the persistent AF patients
ad higher CRP levels than those with paroxysmal AF (14).
nivariate and Multivariate Analyses ofarly AF Recurrences After Cathet r AblationTable 3 Univariate and Multivariate Analyses ofEarly AF Recurrences After Catheter Ablation
p Value Odds Ratio
95% Confidence
Interval
Univariate analysis
Frequent APCs 0.001 20.31 6.813–60.53
Nonsustained AF 0.001 31.67 9.695–103.4
Highest body temperature, °C 0.414 0.735 0.352–1.538
Body temperature, °C 0.141 0.507 0.205–1.252
Highest CRP, mg/dl 0.308 0.761 0.450–1.286
CRP, mg/dl 0.304 0.761 0.452–1.280
Corticosteroid treatment 0.827 1.104 0.453–2.690
Multivariate analysis
Frequent APCs 0.001 15.96 4.000–63.66
Nonsustained AF 0.001 20.57 5.184–81.62
Corticosteroid treatment 0.513 0.631 0.159–2.507
bbreviations as in Table 2.
ox Regression Analysis of AF Recurrencesfter Catheter AblationTable 4 Cox Regressi n Analysis of AF RecurrencesAfter Catheter Ablation
Variables p Value
Hazard
Ratio
95% Confidence
Interval
Highest body temperature, °C 0.008 1.907 1.187–3.063
Highest CRP levels, mg/dl 0.075 1.239 0.979–1.569
Frequent APCs (10 APCs
within 1 min)
0.001 3.560 1.809–7.007
Nonsustained AF 0.001 3.526 1.856–6.697
Corticosteroid treatment 0.031 0.458 0.226–0.929bbreviations as in Table 2.
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October 26, 2010:1463–72 Corticosteroids Suppress AF After Ablationrecent study demonstrated that the leukocyte count was
n independent pre-ablative predictor of AF recurrences
fter PVI (5). These findings suggest that non- or pre-
perative inflammation may play a prominent role in the
tiology, initiation, and maintenance of AF (5,6,15).
It is well-known that AF often occurs several days after
ardiac surgery (9) as well as after successful electrical
ardioversion (6,16). The serum CRP and cytokine levels
orrespond to AF recurrence rates after cardiac surgery (17),
nd CRP levels can be elevated within the first 24 h after
F initiation after successful electrical cardioversion (6). In
he PVI procedure, extensive radiofrequency energy deliv-
red throughout the left atrium may result in significant and
xtensive histopathologic tissue damage (18). Therefore, we
hink that in the genesis of AF shortly after a successful AF
blation, the inflammation surge caused by the procedure is
mportant, and the transient use of very low-dose cortico-
teroids is effective for inhibiting immediate AF recurrences
fter PVI.
In the present study, early AF recurrences occurring
ithin 4 days to 1 month after ablation were not associated
ith an inflammatory response, which is the same result
btained in a previous study (7). Furthermore, in patients
ith early AF recurrences, the prevalence of an AF-free rate
t 14 months did not differ between the 2 groups. Recovered
onduction between the left atrium and PVs and the
ppearance of non-PV foci triggering AF might be respon-
ible for the early AF recurrences (19).
ffect of corticosteroids on late recurrences of AF after
VI. We found that corticosteroid treatment decreased the
verall prevalence of AF recurrence at 14 months post-
blation by preventing immediate AF recurrences caused by
nflammatory responses. Because the biological half-life of
rednisolone is 12 to 36 h and because it was used only for
he initial 3 days after ablation in the present study, the
ffects of prednisolone, including suppression of the inflam-
atory response, could last for more than these first 3 days.
owever, it seems fairly implausible that corticosteroid use
hortly after PVI could prevent reconduction between the
eft atrium and PVs over the long term.
Structural and electrical remodeling commences within a
ew hours of the onset of AF, whereas reverse remodeling
fter restoration of sinus rhythm occurs much more slowly
20). This longer AF-free period after ablation in patients
ith corticosteroids might have enabled the atria to halt any
lectrical or functional remodeling and allowed reverse
emodeling to progress, resulting in a greater AF-free rate at
4 months post-ablation. Atrial tachyarrhythmias also cause
nflammation (21), and such induced inflammation might
ause AF. Corticosteroid treatment administered shortly
fter PVI might halt the relationship between inflammation
nd rapid atrial arrhythmia formation, which may represent
vicious cycle.
tility and significance of early reablation procedures.
he efficacy of an early repeat ablation after the initial
blation procedure has been reported (22). However, severaltudies (2–4,7) and our present results show that a delayed
ure for AF despite early recurrence after PVI is found in a
onsiderable number of patients, and the prevalence in
atients with AF recurring within a few days to 1 month
fter PVI is reported to be as high as 76% (7) and 57% (2),
espectively. Therefore, in patients with early recurrence and
specially with AF recurrence within a few days after the
blation, relatively quick resolution of the AF episodes can
e expected, and an early reablation procedure may not be
ndicated in most of these patients.
tudy limitations. First, this study included a relatively
mall number of patients and a short follow-up period, and
ome patients with asymptomatic AF recurrence might have
een missed. Second, the effect and risk of various doses of
orticosteroids on AF recurrences after PVI were not
xamined or determined. Third, our findings were not
onfirmed by a protocol using different ablation methods,
blation catheters, or energy settings. Fourth, the serum
RP and BT are nonspecific markers of inflammation,
specially in the acute phase, and the origin of those
nflammatory responses after the ablation has not been
larified. Finally, the precise mechanism of corticosteroid
se shortly after PVI for preventing AF in the long term
ould not be clarified.
onclusions
ransient use of small amounts of corticosteroids shortly
fter AF ablation may be effective and safe for preventing
ot only immediate AF recurrences but also AF recurrences
uring the mid-term follow-up period after PVI.
eprint requests and correspondence: Dr. Takashi Koyama,
ardiovascular Division, Institute of Clinical Medicine, Graduate
chool of Comprehensive Human Sciences, University of
sukuba, 1-1-1 Tennodai, Tsukuba 305-8575, Ibaraki, Japan.
-mail: tkoyama-tym@umin.ac.jp.
EFERENCES
1. Shah AN, Mittal S, Sichrovsky TC, et al. Long-term outcome
following successful pulmonary vein isolation: pattern and prediction
of very late recurrence. J Cardiovasc Electrophysiol 2008;19:611–7.
2. Lee SH, Tai CT, Hsieh MH, et al. Predictors of early and late
recurrence of atrial fibrillation after catheter ablation of paroxysmal
atrial fibrillation. J Interv Card Electrophysiol 2004;10:221–6.
3. Oral H, Knight BP, Ozaydin M, et al. Clinical significance of early
recurrence of atrial fibrillation after pulmonary vein isolation. J Am
Coll Cardiol 2002;40:100–4.
4. Richter B, Gwechenberger M, Socas A, et al. Frequency of recurrence
of atrial fibrillation within 48 hours after ablation and its impact on
long-term outcome. Am J Cardiol 2008;101:843–47.
5. Issac TT, Dokainish H, Lakkis NM. Role of inflammation in
initiation and perpetuation of atrial fibrillation: a systematic review of
the published data. J Am Coll Cardiol 2007;50:2021–8.
6. Herna´ndez Madrid A. C-reactive protein and atrial fibrillation. An old
marker looking for a new target. Rev Esp Cardiol 2006;59:94–8.
7. Koyama T, Sekiguchi Y, Tada H, et al. Comparison of characteristics
and significance of immediate-vs-early-vs-non-recurrence of atrial
fibrillation after catheter ablation. Am J Cardiol 2009;103:1249–54.
11
1
1
1
1
1
1
1
1
2
2
2
K
1472 Koyama et al. JACC Vol. 56, No. 18, 2010
Corticosteroids Suppress AF After Ablation October 26, 2010:1463–728. McCabe JM, Smith LM, Tseng ZH, et al. Protracted CRP elevation
after atrial fibrillation ablation. Pacing Clin Electrophysiol 2008;31:
1146–51.
9. Halonen J, Halonen P, Järvinen O, et al. Corticosteroids for the
prevention of atrial fibrillation after cardiac surgery: a randomized
controlled trial. JAMA 2007;297:1562–7.
0. Oral H, Chugh A, Lemola K, et al. Noninducibility of atrial
fibrillation as an end point of left atrial circumferential ablation for
paroxysmal atrial fibrillation: a randomized study. Circulation 2004;
110:2797–801.
1. O’Neill MD, Wright M, Knecht S, et al. Long-term follow-up of
persistent atrial fibrillation ablation using termination as a procedural
endpoint. Eur Heart J 2009;30:1105–12.
2. Stabile G, Bertaglia E, Senatore G, et al. Catheter ablation treatment
in patients with drug-refractory atrial fibrillation: a prospective, multi-
centre, randomized, controlled study (Catheter Ablation For The Cure
Of Atrial Fibrillation Study). Eur Heart J 2006;27:216–21.
3. Cheema A, Vasamreddy CR, Dalal D, et al. Long-term single
procedure efficacy of catheter ablation of atrial fibrillation. J Interv
Card Electrophysiol 2006;15:145–55.
4. Chung MK, Martin DO, Sprecher D, et al. C-reactive protein
elevation in patients with atrial arrhythmias: inflammatory mecha-
nisms and persistence of atrial fibrillation. Circulation 2001;104:
2886–91.
5. Letsas KP, Weber R, Bürkle G, et al. Pre-ablative predictors of atrial
fibrillation recurrence following pulmonary vein isolation: the potential
role of inflammation. Europace 2009;11:158–63. i6. Tieleman RG, Van Gelder IC, Crijns HJ, et al. Early recurrences of
atrial fibrillation after electrical cardioversion: a result of fibrillation-
induced electrical remodeling of the atria? J Am Coll Cardiol 1998;
31:167–73.
7. Zaman AG, Archbold RA, Helft G, et al. Atrial fibrillation after
coronary artery bypass surgery: a model for preoperative risk stratifi-
cation. Circulation 2000;101:1403–8.
8. Grubman FE, Pavri BB, Lyle S, et al. Histopathologic effects of
radiofrequency catheter ablation in previously infarcted human myo-
cardium. J Cardiovasc Electrophysiol 1999;10:336–42.
9. Ouyang F, Antz M, Ernst S, et al. Recovered pulmonary vein
conduction as a dominant factor for recurrent atrial tachyarrhythmias
after complete circular isolation of the pulmonary veins: lessons from
double Lasso technique. Circulation 2005;111:127–35.
0. Allesie M, Ausma J, Schotten U, et al. Electrical, contractile and
structural remodeling during atrial fibrillation. Cardiovasc Res 2002;
54:230–46.
1. Marcus GM, Smith LM, Glidden DV, et al. Markers of inflammation
before and after curative ablation of atrial flutter. Heart Rhythm
2008;5:215–21.
2. Lellouche N, Jaïs P, Nault I, et al. Early recurrence after atrial
fibrillation ablation: prognostic value and effect early reablation.
J Cardiovasc Electrophysiol 2008;19:599–605.
ey Words: ablation y atrial fibrillation y corticosteroid y
nflammatory response y recurrence.
